Home › Triglycerides › NCT07604974

A Study to Assess the Safety, Tolerability and Efficacy of ION775

A Phase 2, Open-label Trial Evaluating the Safety, Tolerability and Efficacy of ION775 in Adults With Hypertriglyceridemia

Who can join

Ages 18 and older · All sexes

Key Inclusion Criteria:

1. Adult males and females with HTG (fasting TG more than or equal to (≥) 350 milligrams per deciliter (mg/dL) \[3.95 millimoles per liter (mmol/L)\] or with sHTG (fasting TG ≥ 500 mg/dL \[5.65 mmol/L\]).
2. Participants should be on standard of care lipid-lowering medications per local guidelines.

Key Exclusion Criteria:

1. Hemoglobin A1c (HbA1c) ≥ 8.5% at Screening.
2. Alanine aminotransferase or aspartate aminotransferase \> 2.0 × upper limit of normal.
3. Total bilirubin \> 1.5 upper limit of normal unless due to Gilbert's syndrome.
4. Estimated GFR \< 30 mL/min/1.73 m\^2.

Note: Other protocol pre-specified inclusion/exclusion criteria may apply.

About the study

The main objective of this study is to evaluate the effect of ION775 on fasting triglyceride (TG) levels in participants with hypertriglyceridemia (HTG) and severe hypertriglyceridemia (sHTG).

What is being tested

• ION775 (drug)

Sponsor: Ionis Pharmaceuticals, Inc. · Participants: 72 · Started: May 12, 2026

Contact the study team

• Ionis Pharmaceuticals, Inc. · Phone: 1-844-828-3770

Official record on ClinicalTrials.gov — NCT07604974

Locations in the U.S.

Conditions

• Triglycerides

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.